QMS Medical Allied Services Intrinsic Value
QMS Medical Allied Services intrinsic value. QMS Medical Allied Services (QMSMEDI) median intrinsic value is ₹85.36 from 10 valuation models (range ₹40–₹189), vs current price ₹131.92 — -35.3% downside (Trading Above Calculated Value), margin of safety -54.5%. For current market price and key ratios, visit QMS Medical Allied Services share price screener.
QMSMEDI Valuation Methods Summary — DCF, Graham Number & P/E
QMS Medical Allied Services intrinsic value across 10 models vs current price ₹131.92 — upside/downside and value range per method. Compare with QMSMEDI DCF valuation to assess whether the stock is under or overvalued.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹85.36 | ₹68.29 - ₹102.43 | -35.3% | EPS: ₹3.88, Sector P/E: 22x |
| Book Value Method | asset | ₹120.00 | ₹108.00 - ₹132.00 | -9.0% | Book Value/Share: ₹60.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹189.47 | ₹170.52 - ₹208.42 | +43.6% | Revenue/Share: ₹94.74, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹126.32 | ₹113.69 - ₹138.95 | -4.2% | EBITDA: ₹24.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹135.83 | ₹108.66 - ₹163.00 | +3.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹39.58 | ₹35.62 - ₹43.54 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹59.95 | ₹53.96 - ₹65.95 | -54.6% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹65.96 | ₹59.36 - ₹72.56 | -50.0% | ROE: 7.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹72.37 | ₹65.13 - ₹79.61 | -45.1% | EPS: ₹3.88, BVPS: ₹60.00 |
| Dividend Yield Method | dividend | ₹39.58 | ₹35.62 - ₹43.54 | -70.0% | DPS: ₹0.50, Target Yield: 2.5% |
QMSMEDI Intrinsic Value vs Market Price — All Valuation Models
QMS Medical Allied Services fair value range ₹40–₹189 vs current market price ₹131.92 across 10 valuation models. Read QMS Medical Allied Services dividend policy for the complete payout history and dividend yield track record.
QMSMEDI Intrinsic Value Analysis — Undervalued or Overvalued?
QMS Medical Allied Services median intrinsic value ₹85.36, current price ₹131.92 — Trading Above Calculated Value by 35.3%, margin of safety -54.5%.
What is the intrinsic value of QMSMEDI?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of QMS Medical Allied Services (QMSMEDI) is ₹85.36 (median value). With the current market price of ₹131.92, this represents a -35.3% variance from our estimated fair value.
The valuation range spans from ₹39.58 to ₹189.47, indicating ₹39.58 - ₹189.47.
Is QMSMEDI undervalued or overvalued?
Based on our multi-method analysis, QMS Medical Allied Services (QMSMEDI) appears to be trading above calculated value by approximately 35.3%.
QMSMEDI Financial Health — Key Ratios vs Industry Benchmarks
QMS Medical Allied Services financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 17.75 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 7.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
QMSMEDI Cash Flow Quality — Operating & Free Cash Flow
QMS Medical Allied Services operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹19 Cr | ₹9 Cr | Positive Free Cash Flow | 7/10 |
| March 2025 | ₹19 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |